Home › Companies › Allogene Therapeutics, Inc. › 2024-2025
Compiled from SEC Form N-PX filings and Allogene Therapeutics, Inc.’s Form 8-K, filed 2025-06-23 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Allogene Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Allogene Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-23 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Elizabeth Barrett | 131,435,760 | -- | -- | 25,929,654 | 33,512,034 | Majority: yes |
| Elect Director: Arie Belldegrun, M.D. | 150,891,245 | -- | -- | 6,474,169 | 33,512,034 | Majority: yes |
| Elect Director: David Chang, M.D., Ph.D. | 153,721,017 | -- | -- | 3,644,397 | 33,512,034 | Majority: yes |
| Proposal 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in | 139,947,868 | 14,233,309 | 3,184,237 | -- | 33,512,034 | Majority: yes |
| Proposal 3. Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's in | 190,111,256 | 414,604 | 351,588 | -- | 0 | Majority: yes |
Source: Allogene Therapeutics, Inc., Form 8-K, filed with the SEC on 2025-06-23 — read the filing on EDGAR.
Each item below shows how the 141 asset managers that disclosed a Allogene Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 8 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Allogene Therapeutics, Inc.’s own tally for this item (“Proposal 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive offic”): 139,947,868 for, 14,233,309 against, per its Form 8-K filed 2025-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 218,598,262 outstanding shares: 64% for, 7% against (71% of the company cast a for/against vote).
The 140 asset managers below cast 77% of the shares they voted on this item FOR (81,372,942 for, 24,820,792 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 0 | 24,530,690 | 0 | 0 | Against |
| Lynx1 Capital Management LP | 11,057,009 | 0 | 0 | 0 | For |
| Citadel | 9,227,602 | 0 | 0 | 0 | For |
| BlackRock | 7,528,499 | 115,146 | 0 | 0 | For |
| T. Rowe Price | 7,266,641 | 0 | 0 | 0 | For |
| Vanguard | 5,159,520 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 4,879,140 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 3,868,750 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,785,168 | 59,933 | 0 | 0 | For |
| Woodline Partners LP | 3,709,357 | 0 | 0 | 0 | For |
| Foresite Capital Management VI LLC | 3,448,275 | 0 | 0 | 0 | For |
| JPMorgan | 3,182,836 | 0 | 0 | 0 | For |
| Wildcat Capital Management, LLC | 0 | 0 | 2,920,787 | 0 | Abstain |
| Vida Ventures Advisors, LLC | 1,798,163 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 1,785,270 | 0 | 0 | 0 | For |
| Aberdeen | 1,734,500 | 0 | 0 | 0 | For |
| State Street | 1,481,594 | 19 | 0 | 0 | For |
| DAFNA Capital Management LLC | 1,380,118 | 0 | 0 | 0 | For |
| GILEAD SCIENCES, INC. | 1,156,689 | 0 | 0 | 0 | For |
| Charles Schwab | 857,659 | 0 | 0 | 0 | For |
| BBR PARTNERS, LLC | 798,899 | 0 | 0 | 0 | For |
| TPG GP A, LLC | 675,000 | 0 | 0 | 0 | For |
| Northern Trust | 649,205 | 0 | 0 | 0 | For |
| Fidelity | 492,571 | 0 | 0 | 0 | For |
| Equitable | 436,753 | 0 | 0 | 0 | For |
Showing the 25 largest of 140 asset managers. See all 140 in the interactive database.
Combines 2 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: Arie Belldegrun, M.D.”): 150,891,245 for, 6,474,169 withheld, per its Form 8-K filed 2025-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 218,598,262 outstanding shares: 69% for, 3% withheld (72% of the company cast a for/withheld vote).
The 47 asset managers below cast 100% of the shares they voted on this item FOR (26,599,370 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 12,265,330 | 0 | 0 | 0 | For |
| Vanguard | 5,033,780 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,096,572 | 0 | 0 | 0 | For |
| BlackRock | 2,062,716 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 1,785,270 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 867,250 | 0 | Abstain |
| Equitable | 214,715 | 0 | 222,038 | 0 | Abstain |
| Charles Schwab | 428,818 | 0 | 0 | 0 | For |
| JPMorgan | 292,432 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 273,875 | 0 | 0 | 0 | For |
| Fidelity | 263,240 | 0 | 0 | 0 | For |
| Lincoln Financial | 137,536 | 0 | 111,015 | 0 | For |
| Global X | 241,564 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 146,779 | 0 | Abstain |
| Zacks Trust | 137,161 | 0 | 0 | 0 | For |
| State Street | 45 | 0 | 120,405 | 0 | Abstain |
| John Hancock | 81,376 | 0 | 10,737 | 0 | For |
| Northern Trust | 76,818 | 0 | 0 | 0 | For |
| Pacific Life | 68,912 | 0 | 0 | 0 | For |
| ETF Series Solutions | 0 | 0 | 68,858 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 67,245 | 0 | Abstain |
| Brighthouse | 0 | 0 | 60,835 | 0 | Abstain |
| ETFis Series Trust I | 0 | 0 | 60,814 | 0 | Abstain |
| Bridge Builder Trust | 57,984 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 0 | 44,900 | 0 | Abstain |
Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: David Chang, M.D., Ph.D.”): 153,721,017 for, 3,644,397 withheld, per its Form 8-K filed 2025-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 218,598,262 outstanding shares: 70% for, 2% withheld (72% of the company cast a for/withheld vote).
The 47 asset managers below cast 100% of the shares they voted on this item FOR (27,911,187 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 12,265,330 | 0 | 0 | 0 | For |
| Vanguard | 5,033,780 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,096,572 | 0 | 0 | 0 | For |
| BlackRock | 2,062,716 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 1,785,270 | 0 | 0 | 0 | For |
| Aberdeen | 867,250 | 0 | 0 | 0 | For |
| Equitable | 436,753 | 0 | 0 | 0 | For |
| Charles Schwab | 428,818 | 0 | 0 | 0 | For |
| JPMorgan | 292,432 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 273,875 | 0 | 0 | 0 | For |
| Fidelity | 263,240 | 0 | 0 | 0 | For |
| Lincoln Financial | 231,336 | 0 | 17,215 | 0 | For |
| Global X | 241,564 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 146,779 | 0 | Abstain |
| Zacks Trust | 137,161 | 0 | 0 | 0 | For |
| State Street | 120,420 | 0 | 30 | 0 | For |
| John Hancock | 81,376 | 0 | 10,737 | 0 | For |
| Northern Trust | 76,818 | 0 | 0 | 0 | For |
| Pacific Life | 68,912 | 0 | 0 | 0 | For |
| ETF Series Solutions | 0 | 0 | 68,858 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 67,245 | 0 | Abstain |
| Brighthouse | 0 | 0 | 60,835 | 0 | Abstain |
| ETFis Series Trust I | 0 | 0 | 60,814 | 0 | Abstain |
| Bridge Builder Trust | 57,984 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 0 | 44,900 | 0 | Abstain |
Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.
Combines 2 wordings of this item as funds reported it.
84% Majority: yes · of votes cast
Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: Elizabeth Barrett”): 131,435,760 for, 25,929,654 withheld, per its Form 8-K filed 2025-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 218,598,262 outstanding shares: 60% for, 12% withheld (72% of the company cast a for/withheld vote).
The 47 asset managers below cast 100% of the shares they voted on this item FOR (10,761,766 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 0 | 0 | 12,265,330 | 0 | Abstain |
| Vanguard | 2,964,570 | 0 | 2,069,210 | 0 | For |
| T. Rowe Price | 3,096,572 | 0 | 0 | 0 | For |
| BlackRock | 1,681,891 | 0 | 380,825 | 0 | For |
| PRIMECAP Odyssey Funds | 1,785,270 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 867,250 | 0 | Abstain |
| Equitable | 55,559 | 0 | 381,194 | 0 | Abstain |
| Charles Schwab | 0 | 0 | 428,818 | 0 | Abstain |
| JPMorgan | 292,432 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 273,875 | 0 | 0 | 0 | For |
| Fidelity | 217,218 | 0 | 46,022 | 0 | For |
| Lincoln Financial | 137,536 | 0 | 111,015 | 0 | For |
| Global X | 0 | 0 | 241,564 | 0 | Abstain |
| Delaware/Macquarie | 0 | 0 | 146,779 | 0 | Abstain |
| Zacks Trust | 137,161 | 0 | 0 | 0 | For |
| State Street | 45 | 0 | 120,405 | 0 | Abstain |
| John Hancock | 81,376 | 0 | 10,737 | 0 | For |
| Northern Trust | 0 | 0 | 76,818 | 0 | Abstain |
| Pacific Life | 0 | 0 | 68,912 | 0 | Abstain |
| ETF Series Solutions | 0 | 0 | 68,858 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 67,245 | 0 | Abstain |
| Brighthouse | 0 | 0 | 60,835 | 0 | Abstain |
| ETFis Series Trust I | 0 | 0 | 60,814 | 0 | Abstain |
| Bridge Builder Trust | 0 | 0 | 57,984 | 0 | Abstain |
| Blackstone Alternative Investment Funds | 0 | 0 | 44,900 | 0 | Abstain |
Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.
99.7% Majority: yes · of votes cast
Allogene Therapeutics, Inc.’s own tally for this item (“Proposal 3. Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP”): 190,111,256 for, 414,604 against, per its Form 8-K filed 2025-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 218,598,262 outstanding shares: 87% for, 0.2% against (87% of the company cast a for/against vote).
The 47 asset managers below cast 100% of the shares they voted on this item FOR (28,483,311 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 12,265,330 | 0 | 0 | 0 | For |
| Vanguard | 5,033,780 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,096,572 | 0 | 0 | 0 | For |
| BlackRock | 2,062,716 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 1,785,270 | 0 | 0 | 0 | For |
| Aberdeen | 867,250 | 0 | 0 | 0 | For |
| Equitable | 436,753 | 0 | 0 | 0 | For |
| Charles Schwab | 428,818 | 0 | 0 | 0 | For |
| JPMorgan | 292,432 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 273,875 | 0 | 0 | 0 | For |
| Fidelity | 263,240 | 0 | 0 | 0 | For |
| Lincoln Financial | 248,551 | 0 | 0 | 0 | For |
| Global X | 241,564 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 146,779 | 0 | 0 | 0 | For |
| Zacks Trust | 137,161 | 0 | 0 | 0 | For |
| State Street | 120,450 | 0 | 0 | 0 | For |
| John Hancock | 92,113 | 0 | 0 | 0 | For |
| Northern Trust | 76,818 | 0 | 0 | 0 | For |
| Pacific Life | 68,912 | 0 | 0 | 0 | For |
| ETF Series Solutions | 68,858 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 67,245 | 0 | 0 | 0 | For |
| Brighthouse | 60,835 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 60,814 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 57,984 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 44,900 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.
Ranked by the number of Allogene Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 218,598,262 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Capital Group | 11.22% |
| 2 | Lynx1 Capital Management LP | 5.06% |
| 3 | Citadel | 4.22% |
| 4 | BlackRock | 3.50% |
| 5 | T. Rowe Price | 3.32% |
| 6 | Vanguard | 2.36% |
| 7 | PRIMECAP MANAGEMENT CO/CA/ | 2.23% |
| 8 | Frazier Life Sciences Management, L.P. | 1.77% |
| 9 | Goldman Sachs | 1.76% |
| 10 | Woodline Partners LP | 1.70% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Pfizer Inc. | 10.08% | 13D |
| TPG GP A, LLC | 8.56% | DEF14A |
| BlackRock | 8.20% | 13F |
| Arie Belldegrun, M.D. | 6.16% | 13G |
| David D. Chang, M.D., Ph.D. | 5.63% | 13G |
| David Chang, M.D., Ph.D. | 5.05% | DEF14A |
| Citadel Advisors | 4.71% | 13F |
| Vanguard Group | 3.69% | 13F |
| FMR (Fidelity) | 3.38% | 13F |
| Kenneth Griffin | 3.14% | 13G |
Percentages above are of 218,598,262 shares outstanding, as reported by Allogene Therapeutics, Inc. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Allogene Therapeutics, Inc.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Allogene Therapeutics, Inc.'s shareholder meeting held 2025-06-18, in the 2024-2025 proxy season, 141 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 809 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 91% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Allogene Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-23.
Allogene Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.